^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bexobrutideg (NX-5948)

    i
    Other names: NX-5948, NX 5948, NX5948
    Associations

    News

    Trials
    Company:
    Nurix Therap
    Drug class:
    BTK degrader
    Related drugs:
    Associations

    News

    Trials
    3d
    Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets (clinicaltrials.gov)
    P1, N=18, Recruiting, Nurix Therapeutics, Inc. | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Feb 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    bexobrutideg (NX-5948)
    1m
    A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) (clinicaltrials.gov)
    P2, N=100, Recruiting, Nurix Therapeutics, Inc.
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    bexobrutideg (NX-5948)
    9ms
    A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=32, Completed, Nurix Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    bexobrutideg (NX-5948)
    9ms
    NX-5948-303: Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 (clinicaltrials.gov)
    P1, N=8, Completed, Nurix Therapeutics, Inc. | Recruiting --> Completed
    Trial completion
    |
    bexobrutideg (NX-5948)
    10ms
    Bruton Tyrosine Kinase Degraders: Current Concepts. (PubMed, Am J Clin Oncol)
    While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance-both intrinsic and acquired-poses a significant challenge, often associated with BTK mutations like C481S...Agents such as NRX-0492, BGB-16673, NX-5948, NX-2127, HZ-Q1060, ABBV-101, and AC676 have shown significant BTK degradation in preclinical and early clinical trials...These BTK degraders have demonstrated favorable safety profiles, with manageable adverse events, and offer a novel therapeutic avenue for patients with BTKi-resistant malignancies. As clinical trials progress, these degraders hold the potential to significantly enhance treatment outcomes, offering a new frontier in personalized cancer therapy.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S
    |
    Imbruvica (ibrutinib) • zelebrudomide (NX-2127) • ABBV-101 • NRX0492 • bexobrutideg (NX-5948) • catadegbrutinib (BGB-16673)
    10ms
    BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL. (PubMed, Cancers (Basel))
    We focus on four agents which are under investigation in B-cell malignancies in early clinical trials: BGB-16673, NX-2127, NX-5948, and AC676. Further trials investigating these agents in combination with other targeted CLL agents may help to further understand their applicability. An effective, tolerable oral class of drugs would be invaluable in the treatment of patients with multiply relapsed CLL/SLL.
    Clinical data • Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    zelebrudomide (NX-2127) • bexobrutideg (NX-5948) • catadegbrutinib (BGB-16673)
    10ms
    A Validated Liquid Chromatography-Tandem Mass Spectrometry Assay for the Determination of NX-5948 in Beagle Dog Plasma: Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr)
    NX-5948 was demonstrated to be stable under the present storage conditions. After validation, the method was successfully applied for the quantification of NX-5948 in beagle dog plasma after oral and intravenous administration of the NX-5948.
    PK/PD data • Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    bexobrutideg (NX-5948)
    11ms
    NX-5948-301: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=492, Recruiting, Nurix Therapeutics, Inc. | N=292 --> 492 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Dec 2025 --> Jan 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    bexobrutideg (NX-5948)
    1year
    Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets (clinicaltrials.gov)
    P1, N=18, Recruiting, Nurix Therapeutics, Inc.
    New P1 trial
    |
    bexobrutideg (NX-5948)
    1year
    A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Nurix Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bexobrutideg (NX-5948)
    1year
    Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 (clinicaltrials.gov)
    P1, N=8, Recruiting, Nurix Therapeutics, Inc.
    New P1 trial
    |
    bexobrutideg (NX-5948)
    1year
    A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=32, Recruiting, Nurix Therapeutics, Inc.
    New P1 trial
    |
    bexobrutideg (NX-5948)